InvestorsHub Logo
Followers 51
Posts 4564
Boards Moderated 0
Alias Born 12/14/2009

Re: guy3 post# 1492

Wednesday, 04/29/2015 3:29:31 PM

Wednesday, April 29, 2015 3:29:31 PM

Post# of 3683
I agree.But you should look at the cashburn: missing primary and secondary endpoints won't convince the Japanese authorities to grant commercialization while doing phase 3. It won't convince the FDA or EMA either to grant breakthrough designation. It will take a lot of money and patience (2-3 years at least).